Professor Paul Workman Joins Nuevolution as Scientific Advisor

Nuevolution is pleased to announce that Professor Paul Workman has joined as Scientific Advisor. Paul brings a vast knowledge and expertise within the oncology field to Nuevolution, as well as profound understanding of bridging research discoveries with commercial value.

Professor Workman is an exceptionally experienced research leader, having achieved a high level of success in academia, biotech companies and the pharmaceutical industry. He is a biochemist and cancer pharmacologist by training and he has worked at a number of academic institutions including Cambridge University, UK, Stanford University, California and the University of Glasgow, UK before moving to AstraZeneca, Alderley Park, UK as Head of the Cancer Bioscience Section in 1993.

In 1997, Paul joined The Institute of Cancer Research, London to build the Cancer Research UK Cancer Therapeutics Unit and co-founded two successful biotech companies, Piramed Pharma and Chroma Therapeutics. As well as being the Director of the ICR’s CTU and Harrap Professor of Pharmacology and Therapeutics, Paul was recently appointed Interim Chief Executive of ICR, having been Deputy CEO for the last 3 years. Paul has received many scientific achievement awards including the American Association of Cancer Research Team Science Award (Team Leader) in 2012 and Cancer Research UK Translational Cancer Research Prize (Joint Leader of HSP90 Team) in 2013. In addition, he has received both the Sosnovsky Award in Cancer Therapy (2010) and the World Entrepreneur of the Year Award (2012) from the Royal Society of Chemistry and earlier this year received the international Raymond Bourgine Award for excellence in cancer research.

“We are happy to further expand our collaboration with Paul and to have him join our expert advisory panel. Paul and his team at ICR have had a truly remarkable success rate and an outstanding track record in bringing compounds to the clinic” said Thomas Franch, CSO of Nuevolution. “We are certain that Paul’s expertise will help accelerate our oncology projects further to meet our ambitions of providing novel compounds for cancer treatment.”

Professor Workman said: “I am delighted to join Nuevolution’s advisors and am impressed by their proprietary Chemetics technologies that provide an unprecedented capability for the identification of drug leads and a strong potential to address major unmet medical needs”.